Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill could help restore skin color in vitiligo patients

NCT ID NCT07625891

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study tests an experimental drug called D-2570 in 160 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take either D-2570 or a placebo pill once daily for 24 weeks, with an optional 24-week extension. The goal is to see if the drug safely helps bring back skin color, especially on the face.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
D-2570 (an oral drug taken as a pill once daily)
What this could lead to
If successful, this could point toward a new daily pill treatment to help restore skin color in people with vitiligo.
What could go wrong
This is an early Phase 2 trial with only 160 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntarily signs informed consent and complies with study procedures. * Age 18-65 years, male or female. * Clinical diagnosis of non-segmental vitiligo at screening. * F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo. * Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose. Exclusion Criteria: * \- Segmental, mixed vitiligo or other concurrent pigmentary/active skin disorders interfering with study assessment. * Over 33% facial or total vitiligo lesions with leukotrichia. * Pregnant or breastfeeding females. * Active, latent or inadequately treated tuberculosis infection. * Positive HIV, active HBV/HCV infection, or untreated syphilis. * Current or history of severe herpes infection. * Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment. * Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study. * Uncontrolled thyroid disease, severe cardiovascular/cerebrovascular disease or other unstable severe systemic disorders. * Severe psychiatric disease, suicidal ideation, or alcohol/drug abuse within 6 months. * Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia). * Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing. * Clinically significant abnormal lab results: elevated liver/renal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts. * History of severe drug hypersensitivity or drug-related toxicity. * Any condition that may impair protocol compliance or study participation per investigator judgment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-segmental vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Huashan Hospital, Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 201203, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.